Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

499 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
nab-Paclitaxel Plus Durvalumab in Patients With Previously Treated Advanced Stage Non-small Cell Lung Cancer (ABOUND.2L+).
Morgensztern D, Dols MC, Ponce Aix S, Postmus PE, Bennouna J, Fischer JR, Juan-Vidal O, Stewart DJ, Ardizzoni A, Bhore R, Wolfsteiner M, Reck M, Talbot D, Govindan R, Ong TJ. Morgensztern D, et al. Among authors: ardizzoni a. Front Oncol. 2021 Feb 11;10:569715. doi: 10.3389/fonc.2020.569715. eCollection 2020. Front Oncol. 2021. PMID: 33643895 Free PMC article.
Cisplatin/paclitaxel vs cisplatin/teniposide for advanced non-small-cell lung cancer. The EORTC Lung Cancer Cooperative Group. The European Organization for Research and Treatment of Cancer.
Giaccone G, Postmus PE, Splinter TA, Diaz-Puente M, Van Zandwijk N, Scagliotti G, Ardizzoni A, Van Meerbeeck J, Debruyne C. Giaccone G, et al. Among authors: ardizzoni a. Oncology (Williston Park). 1997 Apr;11(4 Suppl 3):11-4. Oncology (Williston Park). 1997. PMID: 9144684 Clinical Trial.
Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group.
Ardizzoni A, Hansen H, Dombernowsky P, Gamucci T, Kaplan S, Postmus P, Giaccone G, Schaefer B, Wanders J, Verweij J. Ardizzoni A, et al. J Clin Oncol. 1997 May;15(5):2090-6. doi: 10.1200/JCO.1997.15.5.2090. J Clin Oncol. 1997. PMID: 9164222 Clinical Trial.
Role of recombinant interferon-gamma maintenance in responding patients with small cell lung cancer. A randomised phase III study of the EORTC Lung Cancer Cooperative Group.
van Zandwijk N, Groen HJ, Postmus PE, Burghouts JT, ten Velde GP, Ardizzoni A, Smith IE, Baas P, Sahmoud T, Kirkpatrick A, Dalesio O, Giaccone G. van Zandwijk N, et al. Among authors: ardizzoni a. Eur J Cancer. 1997 Oct;33(11):1759-66. doi: 10.1016/s0959-8049(97)00174-3. Eur J Cancer. 1997. PMID: 9470829 Clinical Trial.
Reduction of chemotherapy-induced febrile leucopenia by prophylactic use of ciprofloxacin and roxithromycin in small-cell lung cancer patients: an EORTC double-blind placebo-controlled phase III study.
Tjan-Heijnen VC, Postmus PE, Ardizzoni A, Manegold CH, Burghouts J, van Meerbeeck J, Gans S, Mollers M, Buchholz E, Biesma B, Legrand C, Debruyne C, Giaccone G; European Organisation for Research and Treatment of Cancer-Lung Cancer Group. Tjan-Heijnen VC, et al. Among authors: ardizzoni a. Ann Oncol. 2001 Oct;12(10):1359-68. doi: 10.1023/a:1012545507920. Ann Oncol. 2001. PMID: 11762805 Free article. Clinical Trial.
Reply to the article "Editorial comments on 'reduction of chemotherapy-induced febrile leucopenia by prophylactic use of ciprofloxacin and roxithromycin in small-cell lung cancer patients: an EORTC double-blind placebo-controlled phase III study'", by P. A. Bunn Jr (Ann Oncol 2001; 12: 1339-1340).
Tjan-Heijnen VC, Postmus PE, Ardizzoni A; European Organisation for Research and Treatment of Cancer, Lung Cancer Group. Tjan-Heijnen VC, et al. Among authors: ardizzoni a. Ann Oncol. 2002 Mar;13(3):485-6; author reply 486-7. doi: 10.1093/annonc/mdf138. Ann Oncol. 2002. PMID: 11996485 Free article. No abstract available.
Standard versus intensified chemotherapy with granulocyte colony-stimulating factor support in small-cell lung cancer: a prospective European Organization for Research and Treatment of Cancer-Lung Cancer Group Phase III Trial-08923.
Ardizzoni A, Tjan-Heijnen VC, Postmus PE, Buchholz E, Biesma B, Karnicka-Mlodkowska H, Dziadziuszko R, Burghouts J, Van Meerbeeck JP, Gans S, Legrand C, Debruyne C, Giaccone G, Manegold C; European Organization for Research and Treatment of Cancer-Lung Cancer Group. Ardizzoni A, et al. J Clin Oncol. 2002 Oct 1;20(19):3947-55. doi: 10.1200/JCO.2002.02.069. J Clin Oncol. 2002. PMID: 12351591 Clinical Trial.
Pemetrexed versus pemetrexed and carboplatin as second-line chemotherapy in advanced non-small-cell lung cancer: results of the GOIRC 02-2006 randomized phase II study and pooled analysis with the NVALT7 trial.
Ardizzoni A, Tiseo M, Boni L, Vincent AD, Passalacqua R, Buti S, Amoroso D, Camerini A, Labianca R, Genestreti G, Boni C, Ciuffreda L, Di Costanzo F, de Marinis F, Crinò L, Santo A, Pazzola A, Barbieri F, Zilembo N, Colantonio I, Tibaldi C, Mattioli R, Cafferata MA, Camisa R, Smit EF. Ardizzoni A, et al. J Clin Oncol. 2012 Dec 20;30(36):4501-7. doi: 10.1200/JCO.2012.43.6758. Epub 2012 Oct 29. J Clin Oncol. 2012. PMID: 23109689 Clinical Trial.
499 results